Tag Archives: risk

The Changing Landscape of Postmarketing Safety Reporting

Drugs are approved for marketing on the basis of clinical trials that are, generally speaking, carried out on relatively small numbers of people.  The goal of these trials are to identify the risks inherent in taking a drug while also … Continue reading

Posted in Clinical Trials | Tagged , , , , , , , , , , , , | 1 Comment

FDASIA, Part 3: Generating Antibiotic Incentives Now (GAIN) and Drug Approval and Patient Access Changes

On 09 July 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA, otherwise known as PDUFA V) was signed into law.  In a 4-part weekly series, we are covering the major changes in FDASIA as follows: Part 1: … Continue reading

Posted in FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , , , , , , , , , , , , | 4 Comments

Conference Recap – 2011 ACRP Global Conference and Exhibition

The 2011 Association of Clinical Research Professionals (ACRP) Global Conference and Exhibition was held on 30 April – 03 May 2011 in Seattle, WA. The conference hosted 2,000 registrants including physicians, nurses, pharmacists, clinical research coordinators, clinical research associates, and other clinical research professionals. Continue reading

Posted in Clinical Trials, Conferences and Meetings | Tagged , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Conference Recap – 2011 ACRP Global Conference and Exhibition

Conference Recap – BayBio 2011

The BayBio Annual Conference 2011 was held on 20-21 April 2011 in Burlingame, CA.  The event was attended by more than 1,000 San Francisco Bay Area biotech and life sciences professionals from over 400 companies. This year’s conference focused on … Continue reading

Posted in Conferences and Meetings, Venture Capital | Tagged , , , , , , , , , , , , , , , , , | Comments Off on Conference Recap – BayBio 2011

New FDA Guidances – March 2011

Each month, Cato Research Regulatory Scientist Cathy Anderson compiles a list of the notable guidance documents released by the FDA.  Here’s a summary of the guidances released in March 2011 (most links go directly to PDF documents). Postmarketing Studies and … Continue reading

Posted in Clinical Trials, FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , | Comments Off on New FDA Guidances – March 2011